Inventiva’s lanifibranor found to have good safety profile following first assessment of carcinogenicity studies’ results
To Present the Latest Findings in its RORγ program at the 256th National Meeting of the American Chemical Society
Reports First-half 2018 Financial Results and Provides a Corporate Update
Announces Positive DSMB Reviews in both NASH and Systemic Sclerosis Phase IIb Trials with Lanifibranor
Of an Investigator Initiated IND Application to Conduct Phase II Study of Lanifibranor in Type 2 Diabetic Patients with Non-Alcoholic Fatty Liver Disease
To Present at the 2018 JMP Securities Life Sciences Conference
Lanifibranor: Phase IIb trial in NASH, recruiting now
Lanifibranor: Phase IIb trial in Systemic Sclerosis.
Odiparcil: Phase IIa in MPSVI, recruiting now
No front page content has been created yet.